OMass Therapeutics is Expanding its Team

November 20, 2018

Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines is expanding and building out its expert team. We value collaboration, continuous learning, free-thinking and innovation at all levels of our company. Our modern headquarters are located in Oxford, an area famous for scientific research and discovery.

Our current vacancies include:
Protein biochemists for purification and expression of membrane-bound and soluble proteins
Mass spectrometrists with experience of native MS
Computational chemists
Bioinformaticians

OMass is developing novel medicines using its suite of proprietary technologies based on high-resolution mass spectrometry of intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation. These platforms are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs.

To find out more please visit the careers section of our website at www.omass.com/careers.

Further information:

JW Communications +44 (0)7818430877
Julia Wilson juliawilsonuk@gmail.com

Notes for Editors:

About OMass Therapeutics

OMass Therapeutics is a private biotechnology company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. For further information please visit the Company’s website at: www.omass.com.

Back To News

Related News

OMass Therapeutics’ Founder & Scientific Advisor Honoured – Professor Carol Robinson wins 2019 Novozymes Prize and Stein & Moore Award –
July 16, 2019

Oxford, 16 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More
OMass Therapeutics appoints Jonathan Montagu as Non-Executive Director
June 12, 2019

Oxford, 12 June 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More
OMass Therapeutics appoints Rosamond Deegan as Chief Executive Officer
May 8, 2019

Oxford, 8 May 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More
DyNAbind and OMass Therapeutics enter collaboration agreement
April 17, 2019

Dresden, Germany, 16.04.2019 – DyNAbind GmbH and OMass Therapeutics have entered a collaboration for the discovery of new fragment- and small…

Read More